150 related articles for article (PubMed ID: 9576012)
41. FN-C1q and C1 INH C1r-C1s complexes as indicators of complement activation in patients with chronic lymphocytic leukaemia.
Hidvégi T; Ermolin GA; Efremov EE; Dikov MM; Kurmanova LV; Vnashenkova GV; Merkulova MV; Kókai M; Panya A; Füst G
Immunol Lett; 1989 Jul; 22(1):1-6. PubMed ID: 2550362
[TBL] [Abstract][Full Text] [Related]
42. The potentiation of human C1-inhibitor by dextran sulphate is transient in vivo: studies in a rat model.
Bos IG; van Mierlo GJ; Bleeker WK; Rigter GM; te Velthuis H; Dickneite G; Hack CE
Int Immunopharmacol; 2001 Aug; 1(8):1583-95. PubMed ID: 11515821
[TBL] [Abstract][Full Text] [Related]
43. Interaction of C1-inhibitor with the C1r and C1s subcomponents in human C1.
Arlaud GJ; Reboul A; Sim RB; Colomb MG
Biochim Biophys Acta; 1979 Jan; 576(1):151-62. PubMed ID: 760802
[TBL] [Abstract][Full Text] [Related]
44. Antibody-independent activation of C1. I. Differences in the mechanism of C1 activation by nonimmune activators and by immune complexes: C1r-independent activation of C1s by cardiolipin vesicles.
Kovacsovics TJ; Peitsch MC; Kress A; Isliker H
J Immunol; 1987 Mar; 138(6):1864-70. PubMed ID: 3029222
[TBL] [Abstract][Full Text] [Related]
45. Regulation of the function of the first component of complement by human C1q receptor.
van den Berg RH; Faber-Krol M; van Es LA; Daha MR
Eur J Immunol; 1995 Aug; 25(8):2206-10. PubMed ID: 7664783
[TBL] [Abstract][Full Text] [Related]
46. Does angiotensin-converting enzyme inhibitor use exacerbate hereditary angioedema?
Hassen GW; Tu TJ; Wei DH; Hwang A; Lamothe R; Costea A; Liu LL; Smith T; Mualim F; Johnston P; Ng JM; Usmani S; Kalantari H
J Emerg Med; 2013 Oct; 45(4):602-8. PubMed ID: 23890533
[TBL] [Abstract][Full Text] [Related]
47. C1q protein binds to the apoptotic nucleolus and causes C1 protease degradation of nucleolar proteins.
Cai Y; Teo BH; Yeo JG; Lu J
J Biol Chem; 2015 Sep; 290(37):22570-80. PubMed ID: 26231209
[TBL] [Abstract][Full Text] [Related]
48. Biosynthesis of the collagen-like C1q molecule and its receptor functions for Fc and polyanionic molecules on macrophages.
Loos M
Curr Top Microbiol Immunol; 1983; 102():1-56. PubMed ID: 6188579
[No Abstract] [Full Text] [Related]
49. The reconstitution of human C1, the first complement component: binding of C1r and C1s to C1q influences the C1q conformation.
Golan MD; Hitschold T; Loos M
FEBS Lett; 1981 Jun; 128(2):281-5. PubMed ID: 6266874
[No Abstract] [Full Text] [Related]
50. Identification of defensin binding to C1 complement.
Panyutich AV; Szold O; Poon PH; Tseng Y; Ganz T
FEBS Lett; 1994 Dec; 356(2-3):169-73. PubMed ID: 7805831
[TBL] [Abstract][Full Text] [Related]
51. The macromolecular structure of the first component of complement.
Assimeh SN; Painter RH
J Immunol; 1975 Aug; 115(2):488-94. PubMed ID: 807640
[TBL] [Abstract][Full Text] [Related]
52. The relationship between the binding ability and the rate of activation of the complement component C1.
Folkerd EJ; Gardner B; Hughes-Jones NC
Immunology; 1980 Sep; 41(1):179-85. PubMed ID: 7429549
[TBL] [Abstract][Full Text] [Related]
53. Inhibition of C1q functions by RHP, a protein elevated in sera from patients with rheumatoid arthritis.
Rosano CL; Braun CB; Hechemy KE; Parhami N; Satoh PS; Hurwitz C
Complement; 1988; 5(2):57-64. PubMed ID: 3259913
[TBL] [Abstract][Full Text] [Related]
54. Kinetics of activation of the first component of complement (C1) by IgG oligomers.
Tschopp J
Mol Immunol; 1982 May; 19(5):651-7. PubMed ID: 6287242
[TBL] [Abstract][Full Text] [Related]
55. Interaction of fucoidan with the proteins of the complement classical pathway.
Tissot B; Montdargent B; Chevolot L; Varenne A; Descroix S; Gareil P; Daniel R
Biochim Biophys Acta; 2003 Sep; 1651(1-2):5-16. PubMed ID: 14499584
[TBL] [Abstract][Full Text] [Related]
56. Conformational changes of the subunits C1q, C1r and C1s of human complement component C1 demonstrated by 125I labeling.
Bauer J; Valet G
Biochim Biophys Acta; 1981 Aug; 670(1):129-33. PubMed ID: 6268178
[TBL] [Abstract][Full Text] [Related]
57. The interaction of human plasma fibronectin with a subunit of the first component of complement, C1q.
Pearlstein E; Sorvillo J; Gigli I
J Immunol; 1982 May; 128(5):2036-9. PubMed ID: 6801128
[TBL] [Abstract][Full Text] [Related]
58. The role of immune complexes in the activation of the first component of human complement.
Ziccardi RJ
J Immunol; 1984 Jan; 132(1):283-8. PubMed ID: 6317744
[TBL] [Abstract][Full Text] [Related]
59. Characterization of C1q, C1s and C-1 Inh synthesized by stimulated human monocytes in vitro.
Reboul A; Prandini MH; Bensa JC; Colomb MG
FEBS Lett; 1985 Oct; 190(1):65-8. PubMed ID: 3876244
[TBL] [Abstract][Full Text] [Related]
60. C1q inhibitor (chondroitin-4-sulfate proteoglycan): structure and function.
Ghebrehiwet B; Galanakis DK
Behring Inst Mitt; 1993 Dec; (93):214-23. PubMed ID: 8172570
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
